Table 1 Baseline and year-1 (visit 5) and year-2 (visit 9) visit characteristics of the study cohort
From: Impact of lipodystrophy on health-related quality of life: the QuaLip study
|  | Baseline (V1) n = 67 | Year-1 (V5) n = 61 | Year-2 (V9) n = 56 |
|---|---|---|---|
Age (years) | 36 (28–50) | 41 (32–54) | 39 (29.75–51.25) |
Gender | |||
Female | 54 (80.60%) | 48 (78.69%) | 46 (82.14%) |
Male | 13 (19.40%) | 13 (21.31%) | 10 (17.86%) |
Type of lipodystrophy | |||
CGL | 16 (23.88%) | 14 (22.95%) | 13 (23.21%) |
APL | 10 (14.93%) | 8 (13.11%) | 9 (16.07%) |
FPLD | 41 (61.19%) | 39 (63.93%) | 34 (60.71%) |
Family history for lipodystrophy | 30 (44.78%) | 31 (50.82%) | 29 (51.79%) |
Diabetes | 61 (91.04%) | 54 (88.52%) | 48 (85.71%) |
Antidiabetics | 47 (70.15%) | 43 (70.49%) | 35 (62.50%) |
Insulin | 40 (59.70%) | 35 (57.38%) | 27 (48.21%) |
Triglyceride lowering drugs | 36 (53.73%) | 27 (44.26%) | 23 (41.07%) |
Hepatic steatosis | 44 (65.67%) | 39 (63.93%) | 36 (64.29%) |
Hyperphagia | 29 (43.28%) | 18 (29.51%) | 22 (39.29%) |
Infertility | 6 (11.11%) | 9 (14.75%) | 6 (10.71%) |
Cardiomyopathy | 9 (13.43%) | 7 (11.48%) | 6 (10.71%) |
Other cardiac disorders | 7 (10.45%) | 6 (9.84%) | 4 (7.14%) |
Pancreatitis | 12 (17.91%) | 8 (13.11%) | 9 (16.07%) |
Ophthalmic disease | 12 (17.91%) | 13 (21.31%) | 14 (25.00%) |
Renal disease | 16 (23.88%) | 14 (22.95%) | 12 (21.43%) |
ESRD requiring dialysis | 3 (4.48%) | 5 (8.20%) | 5 (8.93%) |
Autoimmune disorders | 8 (11.94%) | 6 (9.84%) | 6 (10.71%) |
Height (cm) | 163 (159–168) | 162 (158–168) | 162 (158–170) |
Weight (kg) | 60 (52–75) | 61 (52–72) | 63 (54–73) |
BMI (kg/m2) | 22.82 (20.31–27.12) | 22.81 (20.48–26.12) | 23.75 (21.11–27.12) |
HbA1c (%) | 7.2 (5.9–8.4) | 7.4 (6.0–8.7) | 6.4 (5.7–8.5) |
FBG (mg/dL) | 126 (93–171) | 126 (103–198) | 113 (95–174) |
Triglyceride (mg/dL) | 261 (144–485) | 225 (145–444) | 197 (137–582) |
LDL cholesterol (mg/dL) | 110 (92–130) | 97 (67–123) | 90 (58–121) |
HDL cholesterol (mg/dL) | 34 (29–45) | 36 (31–44) | 31 (24–51) |
Leptin (ng/mL) | 2.91 (0.62–9.77) | NA | 3.82 (1.45–10.87) |
ALT (U/L) | 25 (18–43) | 21 (12–30) | 27 (18–44) |